Melanie Saville, MBBS
Melanie Saville, MBBS, is PATH's Chief Scientific Officer. She leads PATH's product development division, which includes a global team dedicated to the development, introduction, and scale of vaccines, medical devices, and diagnostics.
Dr. Saville is a Fellow of the Academy of Medical Sciences (FMedSci) and chairs the World Health Organization's Product Development for Vaccines Advisory Committee (WHO PDVAC). A physician specializing in virology, she has spent more than two decades developing and licensing vaccines that have reached billions of people worldwide.
Before joining PATH, Dr. Saville served as Executive Director of Vaccine Research and Development at the Coalition for Epidemic Preparedness Innovations (CEPI), where she built a $1.5 billion portfolio that contributed to seven authorized COVID-19 vaccines, including Oxford/AstraZeneca and Moderna. As R&D and manufacturing lead for COVAX, she contributed to the delivery of 1.9 billion vaccine doses globally, with low- and middle-income countries receiving supplies within weeks of high-income nations. She is a principal architect of the 100 Days Mission, the G7/G20-endorsed framework for developing pandemic vaccines within 100 days of a declared threat. Her earlier work at Sanofi Pasteur contributed to the world's first licensed dengue vaccine.
Dr. Saville holds a medical degree, a master's degree in medical virology, and a Bachelor of Science in molecular biology from University College London.
Selected Publications
Delivering Pandemic Vaccines in 100 Days — What Will It Take?
New England Journal of Medicine, 2022 — First author. The strategic framework behind the G7/G20-endorsed 100 Days Mission.
Developing Covid-19 Vaccines at Pandemic Speed
New England Journal of Medicine, 2020 — Cited over 1,500 times; defined the accelerated development paradigm for COVID-19 vaccines.
The COVID-19 Vaccine Development Landscape
Nature Reviews Drug Discovery, 2020
Clinical Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children in Asia
The Lancet, 2014 — First Phase 3 efficacy trial for a dengue vaccine.
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
New England Journal of Medicine, 2015
Intradermal Influenza Vaccine Produces Superior Immunogenicity in Elderly Adults
Journal of Infectious Diseases, 2008
Vaccine Development for Emerging Infectious Diseases
Nature Medicine, 2021
Note: This is a selected list of peer-reviewed publications. Additional publications available through PubMed and institutional repositories.